Morphic Holding, Inc.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF…
Biotechnology
US, Waltham [HQ]
Ratios
7 Sheets · From 2023 to 2017Configuration
Margins, Growth Rates In %
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross Margin | - - | 100.00 | -216.50 | -63.82 | 94.80 | 98.58 | -109.40 | |
| Profit Margin | - - | -709.68 | -255.22 | -100.12 | -476.10 | -83.38 | -29,192.90 | |
| Operating Margin | - - | -733.41 | -276.77 | -104.97 | -484.02 | -89.53 | -34,296.74 | |
|
EPS Growth
|
- - | 18.11 | -38.46 | -2.08 | -78.91 | 41.07 | -131.61 | |
| EPS USD | -127.00 | -104.00 | -144.00 | -147.00 | -263.00 | -155.00 | -359.00 | |
| Return on Assets (ROA) | -72.80 | -12.59 | -17.51 | -18.57 | -22.11 | -16.02 | -21.05 | |
| Return on Equity (ROE) | 56.98 | 45.35 | -30.75 | -30.99 | -27.99 | -16.91 | -21.82 | |
| Return on Invested Capital (ROIC) | 58.20 | 48.43 | -34.06 | -40.13 | -27.65 | -17.98 | -25.61 | |
| Solvency | ||||||||
| Equity Ratio | -100 | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | 2.71 | - - | - - | -12.01 | 1.18 | 1.04 | 0.32 | |
| Debt/Equity | -2.12 | - - | - - | -20.05 | 1.50 | 1.10 | 0.34 | |
| Debt/EBITDA | 121.98 | 771.73 | 219.98 | 483.82 | 420.73 | 87.44 | 31.66 | |
|
Debt/Capitalization
|
-2.17 | - - | - - | -25.08 | 1.48 | 1.09 | 0.34 | |
| Long-Term Debt/Capitalization | -1.07 | - - | - - | - - | 1.13 | 0.67 | 0.10 | |
| Interest Debt per Share USD | 0.03 | - - | - - | -0.95 | 0.14 | 0.22 | 0.06 | |
| Debt Growth | - - | -100.00 | - - | - - | - - | -23.99 | -38.93 | |
| Liquidity | ||||||||
| Current Ratio | 843.42 | 536.12 | 689.03 | 607.12 | 1,093.28 | 2,114.81 | 2,893.64 | |
| Quick Ratio | 824.39 | 532.62 | 680.29 | 917.38 | 1,691.26 | 2,036.10 | 2,842.87 | |
| Cash Ratio | 824.39 | 532.62 | 287.30 | 578.79 | 1,066.63 | 346.09 | 236.43 | |
| Operating Cash Flow Ratio | -600 | 200 | -100 | -100 | -200 | -500 | -400 | |
| Turnover | ||||||||
| Inventory Turnover | - - | - - | - - | -1,006.70 | -44.65 | -220.88 | - - | |
| Receivables Turnover | - - | - - | 489.67 | 614.51 | 858.00 | 15,562.20 | - - | |
| Payables Turnover | - - | - - | 1,039.91 | 1,914.95 | 21.47 | 28.92 | 14.17 | |
|
Asset Turnover
|
- - | 1.77 | 6.86 | 18.54 | 4.64 | 19.21 | 0.07 | |
| Fixed Turnover | - - | 182.20 | 492.66 | 1,724.67 | 267.88 | 1,257.02 | 10.63 | |
| Coverage | ||||||||
| Interest Coverage | - - | - - | - - | - - | - - | -1,388.13 | - - | |
| Asset Coverage | 3,300 | - - | - - | - - | 7,700 | 9,100 | 29,800 | |
| Cash Flow Coverage (CFGR) | -2,446.83 | - - | - - | 157.98 | -1,653.02 | -2,630.98 | -4,791.47 | |
| EBITDA Coverage | - - | - - | - - | - - | - - | -1,300 | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -4.11 | -5.78 | -8.38 | -4.38 | -5.56 | -5.79 | -12.42 | |
|
Price/Earnings (P/E)
|
-2,435.15 | -1,728.95 | -1,194.06 | -2,281.07 | -1,799.77 | -1,726.78 | -804.92 | |
| Price/Earnings Growth (PEG) | - - | 95.47 | -31.05 | -1,094.91 | -22.81 | 42.05 | -6.12 | |
|
Price/Book (P/B)
|
-1,387.62 | -784.04 | 367.14 | 706.94 | 503.75 | 292.02 | 175.64 | |
| Price/Tangible Book (P/TB) | -1,387.62 | -784.04 | 367.14 | 706.94 | 503.75 | 292.02 | 175.64 | |
| Price/Sales (P/S) | - - | 12,270.01 | 3,047.44 | 2,283.81 | 8,568.80 | 1,439.82 | 234,978.73 | |
|
Price/Cash Flow (P/CF)
|
-2,672.90 | 539.75 | -1,242.14 | -2,231.92 | -2,032.22 | -1,009.65 | -1,090.03 | |
| Price/Free CF (P/FCF) | -2,518.50 | 544.45 | -1,180.95 | -2,205.83 | -2,007.68 | -1,006.01 | -1,078.12 | |
| Price/Operating CF (P/OCF) | -2,672.90 | 539.75 | -1,242.14 | -2,231.92 | -2,032.22 | -1,009.65 | -1,090.03 |